The content on this site is intended for healthcare professionals only
Dr Campo talks to ecancertv at EHA 2014 about the genetics of CLL, with specific reference to ibrutinib and the RESONATE trial.
Read the article for more.
Odronextamab shows durable efficacy in R/R follicular lymphoma: 2-Year ELM-2 phase 2 results
Understanding the remaining unmet needs in a post ASCT NDMM setting
Approaches to risk stratification in high risk myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
ESMO 2024: Optimising the personalisation of prostate cancer treatment
